SynthesisDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2026
Management of cT2N0M0 esophageal cancer: a systematic review and meta-analysis.
Synthesis in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of cT2N0M0 esophageal cancer is challenging due to staging limitations and limited evidence. While neoadjuvant therapies benefit advanced disease, its role in cT2N0M0 remains unclear, compounded by underrepresentation in trials and the differing responses to treatment between adenocarcinoma (EAC) and squamous cell carcinoma (SCC). To address this, the ISDE conducted a systematic review and meta-analysis comparing outcomes of neoadjuvant therapy plus surgery (NeoAdj+S) versus primary surgical resection (PSR). MEDLINE, EMBASE, and CENTRAL were searched to 25 November 2024 for English-language studies of adults (≥18 years) with EAC or SCC staged as cT2N0M0. Case series with ≤7 patients, recurrent disease were excluded. Two independent reviewers (YE, SL) selected studies, and extracted data. A random-effects meta-analysis was performed to assess outcomes. Of 299 unique articles screened, 18 studies were included, totaling 14,566 cT2N0 patients. Pooled analysis revealed no statistically significant differences between NeoAdj+S and PSR in terms of 5-year overall survival (OS) (RR 1.08, 95% CI 0.85-1.36; favoring NeoAdj+S), 3-year OS (RR 1.10, 95% CI 0.92-1.30; favoring NeoAdj+S); 5-year disease-free survival (RR 0.88, 95% CI 0.70-1.12; favoring PSR), 30-day mortality (RR 0.91, 95% CI 0.53-1.54; favoring NeoAdj+S), overall complication rates (RR 0.97, 95% CI 0.87-1.08; favoring NeoAdj+S); surgical complications (RR 0.92, 95% CI 0.78-1.08; favoring NeoAdj+S); or medical complications (RR 0.86, 95% CI 0.61-1.23; favoring NeoAdj+S). All included studies demonstrated high risk-of-bias. No clear survival or perioperative advantage was found for NeoAdj+S over PSR. High-quality clinical trials are needed to guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.